NCT07741292RecruitingPhase 4
Niaoduqing Granules in Older Adults With Impaired Kidney Function
A Study of the Clinical Benefits of Niaoduqing Granules in Older Adults With Impaired Renal Function
Source: ClinicalTrials.gov · Last updated 3 Aug 2026
Brief summary (registry, in English)
This prospective real-world study will evaluate the clinical benefits of Niaoduqing Granules in older adults with impaired kidney function. Approximately 300 participants aged over 60 years with stage 3 to 5 chronic kidney disease who are not receiving dialysis will be enrolled at Huashan Hospital, Fudan University. The study will examine whether treatment with Niaoduqing Granules is associated with slower kidney function decline and improvements in nutrition, frailty, and other health outcomes. Participants will receive 5 g of Niaoduqing Granules three times daily after meals for 12 months, while continuing their usual treatment for chronic diseases as directed by their physicians. Kidney function, laboratory results, nutritional status, frailty, cardiovascular and cerebrovascular events, and survival will be assessed during follow-up. Blood, urine, and stool samples will also be collected to study changes in gut microorganisms and blood metabolites that may help explain how Niaoduqing Granules affect health. Participants will be followed for up to 60 months.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 28 Jul 2026
- Start date
- 1 Dec 2025
- Primary completion date
- 30 Nov 2030
- Lead sponsor
- Huashan Hospital
- Diseases
- Chronic kidney disease
- NCT number
- NCT07741292
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 300
- From 1 Dec 2025 to the primary completion date, 30 Nov 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of immunosuppressive therapy, including cyclosporine or tacrolimus, within the 3 months before cohort enrollment, or use of corticosteroids at a dose equivalent to more than 10 mg/day of prednisone.
- Current participation in, or participation within the previous month in, another study related to diet or medication.
Other illness
- Malignancy, severe cardiovascular disease, osteoporosis, or severe hematopoietic system disease.
- Active infection, defined as C-reactive protein greater than 10 mg/L, or current use of nephrotoxic medications.
- Limb paralysis or major limb impairment.
- Severe gastrointestinal disease affecting nutrient absorption.
- Known allergy to Niaoduqing Granules.
- Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Who the study is looking for
- Participants with stage 3 to 5 chronic kidney disease who are not receiving dialysis.
- Age older than 60 years.
- The participant or a family member has sufficient literacy and is able to comply with dietary diary recording and other study-related examinations.
- The underlying cause of chronic kidney disease is clinically stable.
Age in the registry: 61 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Huashan Hospital, Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.